A phase II study of irinotecan-cisplatin plus durvalumab for untreated extensive-stage small cell lung cancer (WJOG13520L, REBORN trial)

被引：0

作者：

Tachihara, M. ^{[1
]}

Shoda, H. ^{[2
]}

Akazawa, Y. ^{[3
]}

Ota, T. ^{[4
]}

Oki, M. ^{[5
]}

Sato, Y. ^{[6
]}

Sugawara, S. ^{[7
]}

Ikeda, S. ^{[8
]}

Yokoyama, T. ^{[9
]}

Kaneda, H. ^{[10
]}

Itoh, S. ^{[11
]}

Bessho, A. ^{[12
]}

Katakami, N. ^{[13
]}

Morita, S. ^{[14
,15
]}

Nakagawa, K. ^{[16
]}

Okamoto, I. ^{[17
]}

Yamamoto, N. ^{[18
]}

机构：

[1] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Resp Med, Kobe, Hyogo, Japan

[2] Hiroshima City Hiroshima Citizens Hosp, Dept Resp Med, Hiroshima, Japan

[3] Natl Hosp Org Toneyama Hosp, Dept Thorac Oncol, Toyonaka, Osaka, Japan

[4] Izumi Municipal Hosp Canc Ctr, Med Oncol, Izumi, Japan

[5] NHO Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan

[6] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan

[7] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan

[8] Kanagawa Cardiovasc & Resp Med, Dept Resp Med, Yokohama, Kanagawa, Japan

[9] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan

[10] Osaka Metropolitan Univ, Grad Sch Med, Clin Oncol Dept, Osaka, Japan

[11] Hyogo Canc Ctr, Resp Med Dept, Akashi, Hyogo, Japan

[12] Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan

[13] Takarazuka City Hosp, Med Oncol Dept, Takarazuka, Hyogo, Japan

[14] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan

[15] Kyoto Univ, Fac Med, Kyoto, Japan

[16] Kindai Univ, Sch Med, Med Oncol Dept, Main Campus, Osaka, Japan

[17] Kyushu Univ, Dept Resp Med, Fukuoka, Japan

[18] Wakayama Med Univ, Internal Med 3, Wakayama, Japan

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.672

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

639P

引用

页码：S1642 / S1642

页数：1

共 50 条

[31] A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer
Bae, Sung Hwa
Ryoo, Hun Mo
Do, Young Rok
Song, Hong Suk
Kwon, Ki Young
Kim, Min Kyoung
Lee, Kyung Hee
Hyun, Myung Soo
Lee, Won Sik
Hur, In Kyong
Baek, Jin Ho
Park, Keon Uk
LUNG CANCER, 2008, 59 (01) : 76 - 80
[32] A Phase II Study of Biweekly Irinotecan and Cisplatin for Patients With Extensive Stage Disease Small Cell Lung Cancer
Ryoo, H.
Bae, S.
Hyun, M.
Lee, K.
Kim, M.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S623 - S623
[33] Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)
Takahashi, T.
Mori, K.
Mizuno, R.
Mamesaya, N.
Kobayashi, H.
Omori, S.
Wakuda, K.
Ono, A.
Naito, T.
Murakami, H.
Kenmotsu, H.
ANNALS OF ONCOLOGY, 2021, 32 : S1165 - S1165
[34] Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC).
Hanna, NH
Einhorn, L
Sandler, A
Langer, C
Hariharan, S
Ansari, R
Ellis, P
Byrne, M
Wang, B
Bunn, P
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1094S - 1094S
[35] Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma - A Phase II trial of the North Central Cancer Treatment Group
Jett, JR
Hatfield, AK
Hillman, S
Bauman, MD
Mailliard, JA
Kugler, JW
Morton, RF
Marks, RS
Levitt, R
CANCER, 2003, 97 (10) : 2498 - 2503
[36] A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer
Sohn, Joo Hyuk
Choi, Hye Jin
Chang, Joon
Kim, Se Kyu
Lee, Chang Geal
Chung, Kyung Young
Kim, Dae Joon
Cho, Byoung Chul
Shin, Sang Joon
Moon, Yong Wha
Kim, Joo-Hang
LUNG CANCER, 2006, 54 (03) : 365 - 370
[37] The phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer
Choi, Hye Jin
Kim, Joo Hang
Sohn, Joo Hyuk
Kim, Se Kyu
Lee, Chang Geol
Cho, Jae Yong
Kim, Yong Tae
ANNALS OF ONCOLOGY, 2006, 17 : 225 - 225
[38] Phase II Trial of Irinotecan plus Nedaplatin (INP) in Treating Patients with Extensive Stage Small Cell Lung Cancer
Li, Chengguang
Huang, Xin-En
Li, Ying
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (02) : 487 - 490
[39] Phase II Study of Irinotecan Plus Cisplatin as First Line therapy in Extensive Small-Cell Lung Cancer
Hwang, Ki Eun
Kim, So Young
Jung, Jong Hoon
Park, Seong Hoon
Park, Jung Hyun
Kim, Hwi Jung
Kim, Hak Ryul
Yang, Sei Hoon
Jeong, Eun Taik
TUBERCULOSIS AND RESPIRATORY DISEASES, 2006, 61 (02) : 143 - 149
[40] E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer
Owonikoko, Taofeek K.
Aisner, Joseph
Wang, Xin Victoria
Dahlberg, Suzanne E.
Rubin, Eric H.
Ramalingam, Suresh S.
Gounder, Murugesan
Rausch, Paul Gregory
Axelrod, Rita S.
Schiller, Joan H.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 171 - 180

← 1 2 3 4 5 →